NCT04695041View on ClinicalTrials.gov

A Healthy Volunteer Study of PBI-4050

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

October 5, 2021

Study Completion Date

October 5, 2021

Conditions
FibrosisInflammation
Interventions
DRUG

PBI-4050/ Placebo

Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days

DRUG

PBI-4050/ Placebo

Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days

DRUG

PBI-4050/ Placebo

Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days

DRUG

PBI-4050/ Placebo

Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days

DRUG

PBI-4050/ Placebo

Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days

Trial Locations (1)

LS2 9LH

Covance CRU, Ltd., Leeds

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY

NCT04695041 - A Healthy Volunteer Study of PBI-4050 | Biotech Hunter | Biotech Hunter